Mega-analysis of meta-analysis: An examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials

Pharmacotherapy

Volumn 16, Issue 6 I, 1996, Pages 1093-1102

  Freeman, Collin D ^a,c   Strayer, Andrew H ^b,c  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c Kansas City Antiinfective Res Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; CEFUROXIME; GENTAMICIN; METRONIDAZOLE; NETILMICIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TINIDAZOLE; TOBRAMYCIN; VANCOMYCIN;

ARTICLE; AUDIOMETRY; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; INFECTION; LEUKOCYTE COUNT; META ANALYSIS; NEPHROTOXICITY; OTOTOXICITY; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; KIDNEY DISEASES; META-ANALYSIS; TREATMENT OUTCOME;

EID: 0029803233     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (85)

1. Glass GV. Primary, secondary, and meta-analysis of research. Educ Researcher 1976;5:3-8.
2. Dew RB, Susla GM. Once-daily aminoglycoside treatment. Infect Dis Clin Pract 1996;5:12-24.
3. Barclay ML, Begg EJ, Hickling KG. What is the evidence for once-daily aminoglycoside therapy? Clin Pharmacokinet 1994;27:32-48.
4. Sturm AW. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis 1989;159:931-7.
5. Giamarellou H, Yiallouros K, Petrikkos G, et al. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. J Antimicrob Chemother 1991;27(suppl C):73-9.
6. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341:335-9.
7. ter Brakk EW, de Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycosides plus β-lactam combination therapy for serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990;89:58-66.
8. de Vries PJ, Verkooyen RP, Leguit P, Verbrugh HA. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis 1990;9:161-8.
9. Rozdzinski E, Kern WV, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β-lactam antibiotics as empirical therapy with febrile neutropenic patients. J Antimicrob Chemother 1993;31:585-98.
10. Hansen M, Achen F, Carstensen C, et al. Once- versus thrice-daily dosing of netilmicin in febrile immunocompromised patients: a randomized, controlled study of efficacy and safety. J Drug Dev 1988;1(suppl 3):119-24.
11. Maller R, Ahrne H, Eilard T, et al. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. J Antimicrob Chemother 1991;27(suppl C):121-8.
12. Mendes de Costa P, Kaufman L. Amikacin once daily plus metronidazole versus amikacin twice daily plus metronidazole in colorectal surgery. Hepatogastroenterology 1992;39:350-4.
13. Nordström L, Ringberg H, Cronberg S, Tjernström, Walder M. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990;25:159-73.
14. Van der Auwera P, Meunier F, Ibrahim S, Kaufman L, Derde MP, Tulkens PM. Pharmacodynamic parameters and toxicity of netilmicin (6 milligrams/kilogram/day) given once daily or in three divided doses to cancer patients with urinary tract infections. Antimicrob Agents Chemother 1991;35:640-7.
15. Hollender LF, Bahnini J, De Manzini N, et al. A multicentric study of netilmicin once daily versus thrice daily in patients with appendicitis and other intra-abdominal infections. J Antimicrob Chemother 1989;23:773-83.
16. Blaser J, Simmen HP, Thurnheer U, König C, Lüthy R. Nephrotoxicity, high frequency ototoxicity, efficacy and serum kinetics of once versus thrice daily dosing of netilmicin in patients with serious infections. J Antimicrob Chemother 1995;36:803-14.
17. Reichley RM, Little JR, Bailey TC. Advantages of extended-interval (EI) aminoglycoside dosing in a 1200-bed institution [abstr]. In: Program and abstracts - Interscience Conference on Antimicrobial Agents and Chemotherapy, 35th annual meeting, San Francisco. Washington, DC: American Society for Microbiology, 1995:A117.
18. Reichley RM, Abraham M, Little JR, Bailey TC. Advantages of extended-interval aminoglycoside (AG) dosing in a predominately elderly population [abstr]. In: Program and abstracts - Interscience Conference on Antimicrobial Agents and Chemotherapy, 35th annual meeting, San Francisco. Washington, DC: American Society for Microbiology, 1995:A118.
19. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296:320-31.
20. Wolf FM. Combined tests. In: Lewis-Beck MS, ed. Meta-analysis: quantitative methods for research synthesis. Newbury Park, CA: Sage, 1986:18-23.
21. Rosenthal R. Combining probabilities. In: Bickman L, Rog DJ, eds. Meta-analytic procedures for social research. Newbury Park, CA: Sage, 1991:89-101.
22. Edgington ES. A normal curve method for combining probability values from independent experiments. J Psychol 1972;82:85-9.
23. Lentino JR, Belknap S, Byrne R. Once daily (QD) aminoglycoside (A) dosing achieves therapeutic peak levels twice those obtained by multiple daily dosing (MDD) with no increase in toxicity [abstr]. In: Program and abstracts - Interscience Conference on Antimicrobial Agents and Chemotherapy, 32nd annual meeting, Anaheim, CA. Washington, DC: American Society for Microbiology, 1992:211.
24. Vreede E. Infections by gram-negative bacilli: humoral defense of the host and antimicrobial therapy. Utrecht: Drukkerij Elinkwijk, 1988:143-65.
25. Aguado JM, Gonzalez P, Martin MA, Fernandez-Chacon T, Ortuno B, Noriega AR. Once-daily (OD) gentamicin (GN) is less toxic for the tubule cells than thrice-daily (TD) dosing [abstr]. Program and abstracts - Interscience Conference on Antimicrobial Agents and Chemotherapy, 33rd annual meeting, New Orleans. Washington, DC: American Society for Microbiology; 1993:1154.
26. Labovitz E, Levison ME, Kaye D. Single-dose daily gentamicin therapy in urinary tract infection. Antimicrob Agents Chemother 1974;6:465-70.
27. Powell SH, Thompson WL, Luthe MA, et al. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983;147:918-32.
28. Maller R, Isaksson B, Nilsson L, Sörén L. A study of amikacin given once versus twice daily in serious infections. J Antimicrob Chemother 1988;22:75-9.
29. Mauracher EH, Lau WY, Kartowisastro H, et al. Comparison of once-daily and thrice-daily netilmicin regimens in serious systemic infections: a multicenter study in six Asian countries. Clin Ther 1989;11:604-13
30. Maller R, Emanuesson BM, Isaksson B, Nilsson L. Amikacin once daily: a new dosing regimen based on drug pharmacokinetics. Scand J Infect Dis 1990;22:575-9.
31. Skopnik H, Heimann G. Once daily aminoglycosides dosing in full term neonates. Pediatr Infect Dis J 1995;14:71-2.
32. Rolland M, Laborie S, Tricoire J. Once-daily amikacin in the newborn [abstr]. In: Program and abstracts - Interscience Conference on Antimicrobial Agents and Chemotherapy, 35th annual meeting, San Francisco. Washington, DC: American Society for Microbiology, 1995:A109.
33. Shankar A, Shankar SD. Gentamicin as once-daily dose therapy in recurrent urinary tract infections in children. Curr Ther Res 1987;41:599-603.
34. Marik PE, Lipman J, Kobilski S, Scribante J. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991;28:753-64.
35. Viscoli C, Dudley M, Ferrea G, et al. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation. J Antimicrob Chemother 1991:27(suppl C):113-20.
36. Bourget P, Fernandez H, Delouis C, Taburet A-M. Pharmacokinetics of tobramycin in pregnant women, safety and efficacy of a once-daily dose regimen. J Clin Pharm Ther 1991;16:167-76.
37. Vigano A, Principi N, Brivio L, Tommasi P, Stasi P, Dalla Villa A. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children. Antimicrob Agents Chemother 1992;36:1499-1503.
38. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119:584-93.
39. Pierre C, Blanchet F, Seta N, et al. Tolerance of once-daily dosing of netilmicin and teicoplanin, alone or in combination, in healthy volunteers. Clin Pharmacol Ther 1988;44:458-66.
40. Krikorian SA. Implementation and assessment of a gentamicin single daily (SDD) protocol [abstr]. In: Program and abstracts - American College of Clinical Pharmacy 1995 winter practice and research forum. Kansas City, MO: American College of Clinical Pharmacy, 1995:84.
41. Van der Auwera P, Klastersky J. Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin. Antimicrob Agents Chemother 1987;31:1061-8.
42. Van der Auwera P. Pharmacokinetic evaluation of single daily dose amikacin. J Antimicrob Chemother 1991;27(suppl C):63-71.
43. Fan ST, Lau WY, Teoh-Chan CH, Lau KF, Mauracher EH. Once daily administration of netilmicin compared with thrice daily, both in combination with metronidazole, in gangrenous and perforated appendicitis. J Antimicrob Chemother 1988;22:69-74.
44. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991;35:399-405.
45. Gilbert DN. Once-daily dosing (OD) of aminoglycoside (AG) is effective and safe for severe bacterial infection [abstr]. In: Program and abstracts - Interscience Conference on Antimicrobial Agents and Chemotherapy, 34th annual meeting, Washington, DC: American Society for Microbiology, 1994:M86.
46. Prins JM, Büller HR, Kuijper EJ, Tange RA, Speelman P. Once-daily gentamicin versus once-daily netilmicin in patients with serious infections - a randomized clinical trial. J Antimicrob Chemother 1994;33:823-35.
47. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross RW, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995;39:650-5.
48. Francoli P, Ruch W, Stamboulian D, et al. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 1995;21:1406-10.
49. Menuier F, Van der Auwera P, Aoun M, Ibrahim S, Tulkens PM. Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study. J Antimicrob Chemother 1991;27(suppl C):129-39.
50. Valcke YJ, Vogelaers DP, Colardyn FA, Pauwels RA. Penetration of netilmicin in the lower respiratory tract after once-daily dosing. Chest 1992;101:1028-32.
51. MacGowan AP, Bedford KA, Blundell E, et al. The pharmacokinetics of once daily gentamicin in neutropenic adults with haemtological malignancy. J Antimicrob Chemother 1994;34:809-12.
52. Tulkens PM. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother 1991;27(suppl C):49-61.
53. Ibrahim S, Derde MP, Kaufman L, et al. Safety, pharmacokinetics and efficacy of once-a-day netilmicin and amikacin versus their conventional schedules in patients suffering from pelvic inflammatory disease. Renal Failure 1990;12:199-203.
54. Tulkens PM, Clerckx-Braun F, Donnez J, et al. Safety and efficacy of aminoglycosides once-a-day: experimental data and randomized controlled evaluation in patients suffering from pelvic inflammatory disease. J Drug Dev 1988;1(suppl 3): 71-82.
55. Vanhaeverbeek M, Siska G, Douchamps J, Herchuelz A. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly. Int J Clin Pharmacol Ther Toxicol 1993;31:153-6.
56. Hustinex W, Hoepelman I. Aminoglycoside dosage regimens: is oace enough? Clin Pharmacokinet 1993;25:427-32.
57. Drusano GI. Role of pharmacokinetics in the outcome of infections. Antimicrob Agents Chemother 1988;32:289-97.
58. MacArthur RD, Lolans V, Zar F, Jackson GG. Biphasic, concentration-dependent and rate-limited, concentration-independent bacterial killing by an aminoglycoside antibiotic. J Infect Dis 1984;150:778-9.
59. Gerber AU, Feller-Segessenmann C. In vivo assessment of in vitro killing patterns of Pseudomonas aeruginosa. J Antimicrob Chemother 1985;15(suppl A):201-6.
60. Jackson GG, Lolans VT, Daikos GL. The inductive role of ionic binding in the bactericidal and postexposure effects of aminoglycoside antibiotics with implications for dosing. J Infect Dis 1990;162:408-13.
61. Daikos GI, Jackson GG, Lolans V, Livermore DM. Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. J Infect Dis 1990;162:414-20.
62. Luft FC, Kleit SA. Renal parenchyma accumulation of aminoglycoside antibiotics in rats. J Infect Dis 1974;130:656-9.
63. Vogelman B, Gudmoundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831-47.
64. Frame PT, Phair JP, Watanakunakorn C, Bannister TWP. Pharmacologic factors associated with gentamicin nephrotoxicity in rabbits. J Infect Dis 1977;135:952-6.
65. Fantin B, Leggett J, Ebert S, Craig WA. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother 1991;35:1413-22.
66. Reiner NE, Bloxham DD, Thompson WL. Nephrotoxicity of gentamicin and tobramycin given once daily or continuously in dogs. J Antimicrob Chemother 1978;4(suppl A):85-101.
67. Bennett WM, Plamp CE, Gilbert DN, Parker RA, Porter GA. The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis 1979;140:576-80.
68. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984;149:443-8.
69. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984;77:657-62.
70. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987;155:93-9.
71. Mann C. Meta-analysis in the breech. Science 1990;249:476-80.
72. Shapiro S. Meta-analysis/schemta-analysis. Am J Epidemiol 1994;140:771-8.
73. Petitti DB. Of babies and bathwater. Am J Epidemiol 1994;140:779-82.
74. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300.
75. Jaeschke R, Oxman AD, Guyatt GH. To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. Am J Med 1990;88:279-86.
76. Littenberg B. Aminophylline treatment in severe, acute asthma. A meta-analysis. JAMA 1988;259:1678-84.
77. Rovers JP, Ilersich AL, Einarson TR. Meta-analysis of parenteral clindamycin dosing regimens. Ann Pharmacother 1995;29:852-8.
78. Galløe AM, Madsen LB, Graudal N, Kampmann JP. Aminoglycosides: single or multiple daily dosing? Lancet 1993;341:1152.
79. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996;124:717-25.
80. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996;37:645-63.
81. Ferriols-Lisart R, Alós-Almiñana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health-Syst Pharm 1996;53:1141-50.
82. Dersimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-88.
83. Einarson RR, Leeder JS, Koren G. A method for meta-analysis of epidemiological studies. Drug Intell Clin Pharm 1988;22:813-24.
84. Glass GV. In defense of generalization. Behavioral Brain Sci 1978;3:394-5.
85. Raz R, Adawi M, Romano S. Intravenous administration of gentamicin once daily versus thrice daily in adults. Eur J Clin Microbiol Infect Dis 1995;14:88-91.